^
Association details:
| Biomarker: | KRAS G12D |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Tagrisso (osimertinib) (EGFR inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Molecular landscape of osimertinib resistance revealed by targeted panel sequencing and patient-derived cancer models in non-small cell lung cancer patients
Published date:
10/09/2018
Excerpt:
The paired baseline and progression sample analysis identified the emergence of acquired mutations, EGFR C797S (n = 1), KRAS G12D (n = 1), and PIK3CA E545K mutations (n = 2), in the progression samples. One of these progression tissue samples with an acquired PIK3CA mutation also lost EGFR....Our multi-layered molecular analysis of osimertinib-resistant patients’ clinical samples and patient-derived cancer models demonstrates a diverse spectrum of osimertinib resistance...
